Bendalis is a leading specialty pharmaceutical company focused on developing and promoting generic and niche proprietary oncology products within Germany and various international markets.
By collaborating with doctors, pharmacists, wholesalers and partners worldwide, Bendalis has an distribution network and access to in-depth information on markets and products.
Founding year of Bendalis GmbH with headquarters in Oberhaching, near Munich.
Market launch of Bendafolin® (folinic acid).
Market launch of five oncology products:
- 5-fluorouracil (5-FU)
Collaboration with EUSA Pharma GmbH in the distribution of Caphosol® for treating oral mucositis.
Expansion of the product portfolio with six generic oncology drugs:
Collaboration with Riemser Arzneimittel AG in the distribution of ALOXI®, an innovative 5-HT3 receptor antagonist for the prophylaxis of chemotherapy-induced nausea and vomiting.
Expansion of the product portfolio to include the supportive care product range, AgainLife Italia:
- OraLife – mouth and throat
- TraLife – throat
- RaLife – skin
- EvaLife – genital region
- GutLife – anal region
Expansion of the product portfolio to include two generic oncology drugs:
- Zoledronic acid
- Ibandronic acid
Expansion of the supportive care product portfolio: KapDolen 30 ml – to alleviate damaged tissue and nerve fibres
Expansion of the supportive care product portfolio: KapDolen 100 ml – to alleviate damaged tissue and nerve fibres
Our sister company was founded in 1989 as a contract manufacturer and active ingredient manufacturer for niche products. As the name suggests, Lyomark supplies sterile lyophilised and liquid products, and has firmly established itself in this sector of the pharmaceutical industry over the last 25 years.
Lyocontract GmbH is a state-of-the-art pharmaceutical manufacturing site with the capabilities of producing liquid and freeze-dried parenteral drugs in vials. The site received its manufacturing license in 2012 and has ever since earned the trust of numerous clients in Germany and abroad. Lyomark Pharma GmbH become majority holder of Lyocontract GmbH in 2017.